The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Phase I Trial of Daily Oral Polyphenon E in Patients With Asymptomatic Rai Stage 0 to II Chronic Lymphocytic Leukemia
Open accessAbstract
Purpose: To define the optimal dose of Polyphenon E for chronic daily administration and tolerability in patients with chronic lymphocytic leukemia (CLL). Patients and Methods: Previously untreated patients with asymptomatic Rai stage 0 to II CLL were eligible for participation. Polyphenon E with a standardized dose of epigallocatechin-3-gallate (EGCG) was administered using the standard phase I design with three to six patients per dose level (range, 400 to 2,000 mg by mouth twice a day). Trough plasma EGCG levels were measured 1 month after initiation of therapy. Response was classified using the National Cancer Institute (NCI) Working Group (WG) Criteria. Results: Thirty-three eligible patients were accrued to dose levels 1 to 8. The maximum-tolerated dose was not reached. The most common adverse effects included transaminitis (33%, all grade 1), abdominal pain (30% grade 1, 0% grade 2, and 3% grade 3), and nausea (39% grade 1 and 9% grade 2). One patient experienced an NCI WG partial remission. Other signs of clinical activity were also observed, with 11 patients (33%) having a sustained ≥ 20% reduction in absolute lymphocyte count (ALC) and 11 (92%) of 12 patients with palpable adenopathy experiencing at least a 50% reduction in the sum of the products of all nodal areas during treatment. Trough plasma EGCG levels after 1 month of treatment ranged from 2.9 to 3,974 ng/mL (median, 40.4 ng/mL). Conclusion: Daily oral EGCG in the Polyphenon E preparation was well tolerated by CLL patients in this phase I trial. Declines in ALC and/or lymphadenopathy were observed in the majority of patients. A phase II trial to evaluate efficacy using 2,000 mg twice a day began in November 2007.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chow, H.-H. S., Hakim, I. A., Vining, D. R., Crowell, J. A., Ranger-Moore, J., Chew, W. M., Celaya, C. A., Rodney, S. R., Hara, Y., & Alberts, D. S. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2549 · Cited by 400
Cited by
Broad targeting of resistance to apoptosis in cancer
Mohammad, R. M., Muqbil, I., Lowe, L., Yedjou, C., Hsu, H.-Y., Lin, L.-T., Siegelin, M. D., Fimognari, C., Kumar, N. B., Dou, Q. P., et al. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.03.001 · Cited by 864
Kim, H.-S., Quon, M. J., & Kim, J.-A. (2014) · Redox Biology · doi:10.1016/j.redox.2013.12.022 · Cited by 804
The safety of green tea and green tea extract consumption in adults – Results of a systematic review
Hu, J., Webster, D., Cao, J., & Shao, A. (2018) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2018.03.019 · Cited by 405
Scientific opinion on the safety of green tea catechins
(ANS), E. P. O. F. A. A. N. S. A. T. F., Younes, M., Aggett, P., Aguilar, F., Crebelli, R., Dusemund, B., Filipič, M., Frutos, M. J., Galtier, P., Gott, D., et al. (2018) · EFSA Journal · doi:10.2903/j.efsa.2018.5239 · Cited by 317
Epigenetic targets of bioactive dietary components for cancer prevention and therapy
Meeran, S. M., Ahmed, A., & Tollefsbol, T. O. (2010) · Clinical Epigenetics · doi:10.1007/s13148-010-0011-5 · Cited by 255
Metadata
- Authors
- Shanafelt, T. D., Call, T. G., Zent, C. S., LaPlant, B., Bowen, D. A., Roos, M., Secreto, C. R., Ghosh, A. K., Kabat, B. F., Lee, M.-J., Yang, C. S., Jelinek, D. F., Erlichman, C., & Kay, N. E.
- Venue
- Journal of Clinical Oncology
- Published
- 2009-08-10
- Volume
- 27
- Issue
- 23
- Pages
- 3808-3814
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2139201942
- Cited by
- 181
- References
- 1
- FWCI
- 7.23
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase I Trial of Daily Oral Polyphenon E in Patients With Asymptomatic Rai Stage 0 to II Chronic Lymphocytic Leukemia. https://app.cochat.ai/papers/10.1200/jco.2008.21.1284
- The paper
- Shanafelt, T. D., Call, T. G., Zent, C. S., LaPlant, B., Bowen, D. A., Roos, M., Secreto, C. R., Ghosh, A. K., Kabat, B. F., Lee, M.-J., Yang, C. S., Jelinek, D. F., Erlichman, C., & Kay, N. E. (2009). Phase I Trial of Daily Oral Polyphenon E in Patients With Asymptomatic Rai Stage 0 to II Chronic Lymphocytic Leukemia. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2008.21.1284
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.